The multiFiltratePRO from Fresenius SE & Co. KGaA - quiet CRRT workhorse for intensive care

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-23, 08:15. Details in the imprint.

multiFiltratePRO from Fresenius SE & Co. KGaA stands in the corner of the intensive care unit, its screen glowing softly while pumps hum at a steady, surprisingly quiet rhythm. Nurses tap the large touch display with gloved fingers, adjusting therapy without leaving the patient’s side.

What multiFiltratePRO is built for

multiFiltratePRO is Fresenius’ platform for continuous renal replacement therapy, designed for hemodynamically unstable patients in intensive care. It supports several CRRT modalities, so ICUs can switch between filtration strategies without changing the machine.

According to chief executive Michael Sen, critical care remains one of the core therapy fields for Fresenius, and multiFiltratePRO sits squarely in this focus as part of the group’s hospital and equipment portfolio. The system is aimed at high-acuity units that need 24-7 reliability more than headline-grabbing features.

Interface and workflow on the ward

The front of the multiFiltratePRO is dominated by a large color touch screen, with a layout that guides staff through priming, connection and therapy steps. Bright color coding and simple icons help new users learn the system after a short in-service.

On a night shift, an ICU nurse can silence alarms, check pressures and adjust anticoagulation dosage with a few taps, without scrolling through dense menus. The tactile feel of the rotary knob and the clear pump door latches matter when hands are tired and time is short.

Therapy flexibility for CRRT

multiFiltratePRO can run continuous veno-venous hemofiltration, hemodialysis and hemodiafiltration, allowing clinicians to tailor clearance and fluid removal to each patient. This flexibility is especially helpful when kidney injury is just one part of a complex multi-organ failure picture.

Fresenius offers matching bloodlines and filters so hospitals can source disposables from a single vendor, which simplifies procurement and quality documentation. For biomedical engineers, having one integrated CRRT platform reduces training effort and spare-part inventory.

Safety features and monitoring

Under the plastic housing, multiFiltratePRO relies on multiple pressure and air sensors, bubble detectors and weighing cells to guard against air embolism, clotting and unintended fluid shifts. Automatic self-tests at start-up support routine safety checks in the ICU.

Visual alarm tiers and distinct sound patterns help staff distinguish between information, warning and critical alarms even from the hallway. In hectic situations, this can be the difference between a quick glance and a full intervention at the bedside.

Where the system has limits

multiFiltratePRO is a dedicated CRRT platform, not a hybrid chronic dialysis system. For hospitals that want to cover chronic and acute therapies with a single machine type, this specialization can be a constraint and requires parallel device strategies.

The unit’s footprint and weight also reflect its ICU focus rather than transport use. Moving the machine between rooms is feasible with its wheeled stand, but frequent transfers across floors or to imaging departments remain cumbersome compared with compact transport systems.

How it fits into Fresenius

For Fresenius, multiFiltratePRO complements chronic dialysis, infusion and hospital services, strengthening the group’s position inside critical care wards rather than only in outpatient dialysis centers. It also creates recurring revenue through filters and disposables.

Fresenius shares (ISIN DE0005785604) are listed on Xetra in euros, and products like multiFiltratePRO form part of the long-term narrative around the company’s hospital and therapy business, even if individual device launches seldom move the share price on their own.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.